Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR
Xiaohui Zeng, Liubao Peng, Peng Ye, Chongqing Tan, Xiaomin Wan
Topics & Concepts
DaratumumabMedicineBortezomibRegimenOncologyInternal medicineMultiple myelomaMultiple Myeloma Research and TreatmentsEconomic and Financial Impacts of CancerCancer Mechanisms and Therapy